Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

NCT07551596 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

NIH

Sponsor class

Conditions

Colorectal Adenocarcinoma
Stage II Colorectal Cancer AJCC v8
Stage III Colorectal Cancer AJCC v8

Interventions

BIOLOGICAL: Balstilimab
PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
BIOLOGICAL: Botensilimab
PROCEDURE: Radiographic Examination

Sponsor

National Cancer Institute (NCI)